1.  To discuss and inform about hydrobromide–quinidine sulfate use for Alzheimer disease–related agitation

2.To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide–quinidine sulfate for Alzheimer disease–related agitation.


Session date: 
Thursday, May 12, 2016 - 8:00am to 9:00am
UCMC W-717
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Samir Bhalla, MD